Over the last several decades, oncology research and cancer treatment have concentrated primarily on the cancer cells. Unfortunately, despite the intensive quest to find new and more effective compounds for chemotherapy, the survival rate of patients has not significantly changed. In 1971 Judah Folkman proposed that a solid tumor cannot grow without inducing angiogenesis. Intensive search for molecules blocking the formation of a tumor-nourishing capillary network has identified several promising agents in experimental models. Some of these angiogenesis inhibitors are in clinical trials, but a clear statement about the efficacy cannot be made yet. What are the current trends in angiogenesis research? What areas should we intensively investigate? Can we find the Holy Grail of cancer therapy in the years to come in order to stop the ineffable suffering of millions of cancer patients? Curr Opin Oncol 2000, 12:89-94
The amount of knowledge describing the molecular alterations necessary for a normal cell to convert to a deadly tumor cell has grown phenomenally over the last two decades. Dozens of tumor suppressor genes and oncogenes have been identified and characterized. Most of these investigations have been performed on already matured and aggressive tumor cell populations. A detectable tumor is in the final stage of its life. It has regressed to an aberrant embryonic phenotype characterized by an insatiable selfishness entirely ignoring external control signals. During the course of maturation some tumor cells manage to activate and recruit endothelial cells, thereby starting the fatal process of tumor tissue expansion. Once a tumor cell population learns to exploit the host's normal developmental mechanisms by acquiring the capacity to induce angiogenesis, a long and tough selection process has rendered the tumor cells extremely flexible, unstable, and aggressive. Conventional therapy is only rarely able to stop the lethal path. What are the players involved in the early stages of tumor development? What are the factors responsible for the formation of a capillary network? Can we destabilize the network formation? Should we look for inhibitors of endothelial cell proliferation, migration, sprouting, or tube formation in vitro or use more laborious in vivo angiogenesis assays to find potent compounds against tumor growth? In general, how can we stop the ruthless ability of tumor cells to exploit the host?
Is hypoxia a critical step in tumor development?
Insufficient vascular supply and the resultant reduction in the tissue oxygen tension can lead to the induction of angiogenesis in order to balance the needs of the tissue. The uncontrolled proliferation of cells in an organ will always lead to a lack of oxygen because the diffusion range of oxygen will sooner or later be exceeded (Fig. 1) . Depending on the vascularization of the organ and the proliferation rate of the premature tumor cells, this stage will be reached at different points in time. In addition, the response to hypoxia is differentially regulated at the level of specific cell types or layers in various organs, raising the possibility of preferential tumor development in areas of increased hypoxia responsiveness [1] . It may be obvious that the initial steps of tumor development, the first non-physiologic cell divisions, are independent of hypoxia and induced by carcinogens, viruses, and so on, but is it possible that at a very early stage hypoxia
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Thomas Boehm-Viswanathan plays a major part in the development of cancer? First, it has been proposed that hypoxia provides a strong selection pressure for the expansion of cells resistant to apoptotic stimuli, in particular for cells acquiring p53 mutations [2••]. Low oxygen selects for "tough" cells. Second, hypoxia can lead to chromosomal breaks at fragile sites, thereby triggering deletion of tumor suppressor genes and gene amplification [3••] . This scenario represents a positive feedback loop whereby the increased proliferation capacity allowed by the alterations of tumor suppressor and oncogenes leads to a hypoxic environment for the cells in the center of the tumor cell cluster, again resulting in genetic alterations (Fig. 1) . In addition, hypoxia is known to induce several growth factors for endothelial cells such as VEGF (vascular endothelial cell growth factor) and angiogenin [4, 5] . Because the induction of known growth factors alone is probably not sufficient to induce the angiogenic switch, defining more carefully the genes that are upregulated or downregulated under hypoxic conditions will be an important research area. Recent developments in gene array technology already allow researchers to analyze the expression level of a significant portion of all the genes in the human genome. The ability to fully induce an angiogenic response is most likely orchestrated by many factors. One reason that some tumor cell populations stay dormant for years may be that it can take decades for tumor cells to gain the capacity to induce adequate capillary formation. This may be a contributing factor to the slow development of prostate cancer. Taken together, it is conceivable that hypoxia is not only involved in the VEGF-mediated angiogenic response of tumor cells, but that it is also one of the critical environmental factors leading to the maturation of tumor cells.
The role of the VEGF family and the VEGF receptors in tumor biology
Several excellent reviews summarize the current stateof-the-art knowledge regarding the VEGF family and the VEGF receptors [6] [7] [8] . The discovery of VEGF changed the field of angiogenesis research because it was the first factor specifically involved in the proliferation and migration of endothelial cells. Most murine and human tumors express VEGF, and the induction of VEGF by hypoxia is seen as a critical step in tumor angiogenesis. VEGF is widely accepted as an important survival factor for endothelial cells, and withdrawal leads to vessel regression. At present the focus of VEGF research in oncology has shifted from basic science to the possibility of blocking VEGF from binding to its receptors and/or to inhibit the tyrosine kinase activity of its receptors, in particular VEGFR-2. Approaches include the use of soluble VEGF receptors or small molecule tyrosine kinase inhibitors [9] . Nevertheless, the inhibition of binding of VEGF to the VEGFR-2 or the blockade of the VEGF-specific downstream signaling pathway may lead to the selective ablation of immature vessels [10•]. This phenomenon may limit anti-90 Cancer biology A, In a normal organ, every parenchymal cell is close to an endothelial cell guaranteeing adequate oxygen supply. B, Known (viruses, chemicals, UV, x rays, and so on) and unknown trigger events induce the proliferation of presumably a single cell. After several cell divisions, a hypoxic gradient develops with decreasing oxygen tension toward the center of the proliferating cells. In addition, the elevated pressure caused by the increased cell number per square unit may squeeze capillaries, thereby further limiting oxygen supply. C, Strong selection pressure for cells surviving a low oxygen environment results in the accumulation of "tough, robust" cells with mutations (eg, in p53). D, The accumulation of cells with mutations in tumor suppressor genes or activation of oncogenes leads to an increased proliferation capacity closing the positive feedback loop. The higher demand for oxygen increases the selection pressure and the genetic instability. The stages A through D are clinically not detectable. E, Finally, some tumor cells gain the ability to induce the formation of a functional endothelial cell network. The expansion process cannot be stopped anymore. 
Angiopoietins-a new and powerful family of angiogenesis regulators
For a long time the TIE1 and TIE2 tyrosine kinase receptors were orphans. Recently, Ang-1 and Ang-2 (angiopoietin-1 and angiopoietin-2) have been identified as ligands for TIE2 whereas the TIE1 receptor still does not want to reveal its partner(s . It is certainly worthwhile to screen for compounds that can block the TIE2 receptor tyrosine kinase and combine them with the already identified VEGF signaling inhibitors. Nevertheless, we should not forget that tumors may find a way to grow without VEGF as it has been shown recently, especially at advanced tumor stages [17] . In this particular model basic fibroblast growth factor and tumor necrosis factor-alpha could
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A, In the embryo, VEGF is required for differentiation and proliferation of endothelial cells and for tubule formation. After VEGF promotes the formation of immature vessels, Ang-1, acting through the Tie2 receptor, promotes the remodeling, maturation, and stabilization of blood vessels, which apparently involves optimizing interactions with surrounding support cells and the extracellular matrix. B, By adulthood, Tie2 is constitutively engaged with Ang-1, and vessels remain in a stable state. When Ang-2 expression is upregulated (for instance, in the normal ovary or by tumor cells), the interaction between Tie2 and Ang-1 is disrupted, and the vessel is destabilized. Once endothelial cells are separated from perivascular cells and the extracellular matrix, they appear particularly plastic and vulnerable. In the presence of VEGF, angiogenesis is promoted; however, lack of stimulatory factors results in the apoptotic regression of destabilized vessels. KO, knockout mouse; L, lumen; Tg, transgenic mouse. 
What do we know about ephrin ligands and Eph receptors?
The family of Eph receptor tyrosine kinases and their ephrin ligands are involved in many physiologic processes. Recently they have attracted increased attention in the angiogenesis field because it has been shown that several molecules are involved in the demarcation of arteries and veins, vascular morphogenesis, endothelial chemotaxis, and angiogenesis [18,19••,20••] . The complexity of the interactions of these molecules is enormous. As shown in Figure 3 , these two protein families are involved in the restriction of cell intermingling and communication, which is potentially important in the interactions of endothelial with endothelial cells and tumor cells [21] . In an in vitro sprouting assay, EphrinB2 was as powerful a stimulator as Ang-1 or VEGF [20••] . Similar to the angiopoietins, manipulation of the ephrin/Eph interactions may disrupt capillary network formation or stabilization. Inhibitory compounds could be valuable players for antiangiogenesis therapy in combination with VEGFR-2 and TIE2 antagonists.
Decoding the postal addresses of different endothelial cell populations
During the last two decades many researchers have attempted to find specific markers on tumor cells to target the tumor cell population. Few molecules have been discovered. From an "angiogenesist's" point of view, the specific targeting of endothelial cells either in tumor tissue or in different organs would open enormous interventional possibilities. Several publications using an in vivo phage homing approach describe first successes [22•,23,24] . Significant advantages of the endothelial compared with the tumor cell targeting strategy are summarized in two recent reviews and in Table 1 [ 22•,25] .
Inhibitors of angiogenesis
Stability is ensured by a balance of the forces. The yin and yang of angiogenesis are potentially determined by the battles between stimulators and inhibitors. Consequently, significant efforts have been devoted to find specific inhibitors of endothelial cell proliferation, migration, and capillary formation using in vitro endothelial cell assays. In vivo angiogenesis models have been used to verify the in vitro results. Many inhibitors of angiogenesis have been described over the years [26, 27] . The publication of two endogenous inhibitors received enormous media attention because complete suppression of a variety of tumors transplanted into the subcutaneous dorsum of mice was reported. Nevertheless, rigorous scientific evaluation of these hollywoodized inhibitors is necessary or maybe not anymore.
Conclusions
Although cancer patients can and should be hopeful that the Holy Grail of cancer therapy will be found in the near future, at the moment of this writing clinically proven blockbuster angiogenesis inhibitors are not available. The National Cancer Institute maintains a web site listing the current clinical trials using angiogenesis inhibitors:
92 Cancer biology (http://cancertrials.nci.nih.gov/nci_cancer_trials/zones/pr essinfo/angio/table.html). Nevertheless, rapid progress in the molecular understanding of the necessary steps to establish or regress an adequate capillary network will provide many targets for intervention. A combination of basic science focusing on the processes involved in physiologic and tumor-associated angiogenesis along with a strong interest of the pharmaceutical industry to provide screening tools should lead to the discovery of compounds able to interfere with the pathways tumor cells need to induce in order to survive. Even if it may not be a single agent, hopefully a cocktail of compounds representing the Holy Grail of cancer research, an amalgam disrupting the deadly process of angiogenesis in cancer patients, may be found in the foreseeable future.
